A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to document the long-term safety and tolerability of
risperidone, formulated as a long-acting injectable, in the treatment of patients with
schizophrenia or schizoaffective disorder; in addition, to evaluate the long-term
effectiveness of long-acting risperidone and its effect on quality of life
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.